The long term goals of the proposed research are to understand the mechanisms underlying regulation of normal and dysregulated cell growth in the vascular system and in neoplastic transformation. To achieve these goals, the laboratory has focused on the platelet-derived growth factor (PDGF) and its inducible cytokine pleiotrophin (PTN) as examples of important growth regulatory molecules. Both PDGF and PTN have different properties to suggest important roles in normal growth and to signal the abnormal growth patterns in the diseased vessel wall and in neoplasia; the similarities between the pathological processes in the vessel wall and neoplasia have suggested important model systems with which to study how PDGF and PTN function at the molecular level. This proposal focuses on PTN as a potential downstream mediator of PDGF. It builds upon preliminary data that establishes the requirement of an intact endogenous PTN signaling system for transformation of a human breast cancer cell line and molecular evidence that independent domains of PTN separately transform cells and promote angiogenesis. Unique models have been established to experimentally dissect the separate pathways that signal transformation and angiogenesis and will be exploited to lay the foundation to design new therapeutic approaches to control abnormal cell growth in man.
The Specific Aims are:
We aim to dissect and analyze the separate domains of pleiotrophin that are responsible for the transformed and angiogenic phenotypes and to use pleiotrophin dominant negative effectors to selectively reverse these phenotypes in vitro and in vivo.
We aim to seek the mechanisms by which pleiotrophin initiates its angiogenic signal.
We aim to analyze the effects of gain of function of PDGF A, of pleiotrophin, and the loss of function pleiotrophin dominant negative effector PTN 1-40 in the vascular system of transgenic mice. The significance of the proposed research is the development of understanding into mechanisms of the angiogenic switch to accelerate tumor growth and the identification of a molecule that is able to trigger the signaling cascade to establish the angiogenic phenotype and transformation and their potential to design therapy. Innovative model systems have been developed to achieve these results and to establish inhibitors of value of tumor cell growth both in vitro and in vivo. These model systems will be of benefit to others in the field.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
2R01HL031102-16
Application #
2704646
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1989-07-01
Project End
2003-06-30
Budget Start
1998-07-01
Budget End
1999-06-30
Support Year
16
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Herradon, Gonzalo; Ezquerra, Laura; Nguyen, Trang et al. (2005) Midkine regulates pleiotrophin organ-specific gene expression: evidence for transcriptional regulation and functional redundancy within the pleiotrophin/midkine developmental gene family. Biochem Biophys Res Commun 333:714-21
Pariser, Harold; Ezquerra, Laura; Herradon, Gonzalo et al. (2005) Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin. Biochem Biophys Res Commun 332:664-9
Zhang, N; Yeh, H J; Zhong, R et al. (1999) A dominant-negative pleiotrophin mutant introduced by homologous recombination leads to germ-cell apoptosis in male mice. Proc Natl Acad Sci U S A 96:6734-8
Liu, J J; Wang, Z Y; Deuel, T F et al. (1999) Imbalanced expression of functionally different WT1 isoforms may contribute to sporadic unilateral Wilms' tumor. Biochem Biophys Res Commun 254:197-9
Silos-Santiago, I; Yeh, H J; Gurrieri, M A et al. (1996) Localization of pleiotrophin and its mRNA in subpopulations of neurons and their corresponding axonal tracts suggests important roles in neural-glial interactions during development and in maturity. J Neurobiol 31:283-96
Kim, H R; Upadhyay, S; Li, G et al. (1995) Platelet-derived growth factor induces apoptosis in growth-arrested murine fibroblasts. Proc Natl Acad Sci U S A 92:9500-4
Wang, Z Y; Qiu, Q Q; Huang, J et al. (1995) Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, wt1, have altered DNA binding specificity and regulate transcription in different ways. Oncogene 10:415-22
Wang, Z Y; Qiu, Q Q; Gurrieri, M et al. (1995) WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein. Oncogene 10:1243-7
Kawahara, R S; Deng, Z W; Denkinger, D J et al. (1994) Role of serine/threonine protein kinases in the induction of JE, a platelet-derived growth factor inducible gene. Biochem Biophys Res Commun 203:1815-20
Deng, Z W; Denkinger, D J; Peterson, K E et al. (1994) Glucocorticoids negatively regulate the transcription of KC, the mouse homolog of MGSA/GRO. Biochem Biophys Res Commun 203:1809-14

Showing the most recent 10 out of 54 publications